BofA Downgrades Moderna To Underperform, Sees Shares Priced For 'Best-Case'

Laboratory Test Tubes

Image Source: Unsplash

As previously reported, BofA analyst Geoff Meacham downgraded Moderna (MRNA) to Underperform from Neutral with an unchanged price target of $150.

With the shares having risen 425% and a further 66% year-to-date in 2021, he sees Moderna being priced for the "best-case," stating that by his analysis cumulative COVID-19 sales of greater than $85B appear to be reflected at current levels.

The stock's momentum has continued despite new COVID-19 vaccine data from Novavax (NVAX) and Johnson & Johnson (JNJ) that should support near-term U.S. and global approvals, noted Meacham, who says volumes and lower price points from Novavax, J&J, Astra-Zeneca (AZN) and others should affect cumulative sales expectations from Moderna.

Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.